Saturday 17 October 2026
Export SILO’s income statement to Excel — free account
Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.18
0.02
−1.67%
Follow SILO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 3 | — |
| (86.11%) | (74.56%) | (99.94%) | (91.23%) | ||
| (67.91%) | (56.30%) | (74.98%) | (70.96%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(93.05%) | (62.75%) | (79.41%) | (96.21%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(7.71) | (8.34) | (4.15) | (3.57) | |
Free Cash Flow |
(4.80) | (4.66) | (3.80) | (3.92) | |
Capital Expenditures |
— | — | 0.05 | (0.58) | |
| Other line items | |||||
Cash ROIC |
(44.12%) | (35.41%) | (32.43%) | (38.76%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.03 | 0.04 | 0.07 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
9,214.80 | 4,752.40 | 3,631.06 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,158.75% | 3,001.11% | 3,583.47% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
3,278.06% | 2,982.92% | 3,069.03% | 0.00% | |
Share Based Compensation of Revenue |
817.36% | 884.17% | 1,952.50% | 0.00% | |
Interest Coverage |
(1,083.18) | (114.76) | (123.87) | (111.82) | |
Operating CF/Net income |
0.95 | 1.10 | 0.79 | 0.75 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 1.19 | (5.75) | |
Revenue per Share |
0.12 | 0.13 | 0.08 | 0.00 | |
Operating CF per Share |
(7.71) | (8.34) | (4.20) | (3.04) | |
Capex per Share |
0.00 | 0.00 | 0.05 | (0.53) | |
Capex to Sales |
0.00 | 0.00 | (0.63) | 0.00 |
Columns are period end dates